Breaking News Instant updates and real-time market news.

HBAN

Huntington Bancshares

$14.81 /

-0.185 (-1.23%)

05:08
01/06/20
01/06
05:08
01/06/20
05:08

Huntington Bancshares downgraded to Hold from Buy at Deutsche Bank

Deutsche Bank analyst Matt O'Connor downgraded Huntington Bancshares to Hold from Buy with a $15 price target.

  • 23

    Jan

HBAN Huntington Bancshares
$14.81 /

-0.185 (-1.23%)

12/13/19
Fly Intel: Top five analyst downgrades
12/13/19 UBS
Huntington Bancshares downgraded to Neutral from Buy at UBS
10/25/19 BofA
Huntington Bancshares downgraded to Neutral from Buy at BofA/Merrill
10/25/19 BofA
Huntington Bancshares downgraded to Neutral from Buy at BofA/Merrill

TODAY'S FREE FLY STORIES

Hot Stocks
Boeing announces order for two 737-800 Boeing Converted Freighters » 18:31
09/20/20
09/20
18:31
09/20/20
18:31
BA

Boeing

$161.07 /

-6.46 (-3.86%)

Boeing has announced a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

09/10/20 Susquehanna
Boeing 737 MAX making progress, but estimates lowered at Susquehanna
09/09/20 Canaccord
Boeing downside risk to production plans seen, says Canaccord
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Morgan Stanley
Boeing initiated with an Underweight at Morgan Stanley
BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

Recommendations
Amgen's sotorasib update 'Incrementally positive,' says Piper Sandler » 17:14
09/20/20
09/20
17:14
09/20/20
17:14
AMGN

Amgen

$248.01 /

-0.22 (-0.09%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

09/18/20 Piper Sandler
Amgen sotosarib Phase 1 data a good news/bad news event, says Piper Sandler
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

On The Fly
Box Office Battle: ‘Tenet' stays on top, crosses $250M globally » 16:28
09/20/20
09/20
16:28
09/20/20
16:28
T

AT&T

$28.92 /

-0.16 (-0.55%)

, CMCSA

Comcast

$45.26 /

-0.35 (-0.77%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, SNE

Sony

$78.99 /

+1.44 (+1.86%)

, LGF.A

Lionsgate

$10.41 /

+0.035 (+0.34%)

, LGF.B

Lionsgate

$9.62 /

+0.05 (+0.52%)

, DIS

Disney

$128.66 /

-1.49 (-1.14%)

, VIACA

ViacomCBS

$33.03 /

+0.18 (+0.55%)

, VIAC

ViacomCBS

$30.16 /

-0.1 (-0.33%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

T AT&T
$28.92 /

-0.16 (-0.55%)

08/31/20
Fly Intel: Top five analyst downgrades
08/31/20 Scotiabank
Scotiabank downgrades AT&T to Underperform on spectrum costs, share losses
08/31/20 Scotiabank
AT&T downgraded to Underperform from Sector Perform at Scotiabank
07/24/20 RBC Capital
AT&T price target lowered to $32 from $38 at RBC Capital
CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

09/18/20 Rosenblatt
Rosenblatt would be buyer on any Roku weakness amid latest Comcast 'tiff'
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
08/24/20 BWS Financial
Xperi initiated with a Buy at BWS Financial
08/03/20 Deutsche Bank
Comcast price target raised to $53 from $47 at Deutsche Bank
CMCSK Comcast
$0.00 /

+ (+0.00%)

07/01/20
Fly Intel: Top five analyst upgrades
04/28/20 Wells Fargo
SeaWorld price target lowered to $16 from $36 at Wells Fargo
04/17/20 Oppenheimer
Comcast downgraded to Perform from Outperform at Oppenheimer
SNE Sony
$78.99 /

+1.44 (+1.86%)

08/17/20
Loeb's Third Point buys Alibaba, makes a top holding, during second quarter
08/05/20 Oppenheimer
Sony price target raised to $100 from $70 at Oppenheimer
07/30/20
Fly Intel: Top five analyst initiations
07/29/20 Goldman Sachs
Sony resumed with a Conviction Buy at Goldman Sachs
LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

09/02/20 Barrington
Lionsgate price target raised to $14 from $10 at Barrington
08/18/20 Barrington
Lionsgate upside 'may be achievable' says Barrington
07/13/20 Goldman Sachs
Lionsgate initiated with a Neutral at Goldman Sachs
06/18/20 Cowen
Lionsgate remain underappreciated OTT play, says Cowen
LGF.B Lionsgate
$9.62 /

+0.05 (+0.52%)

05/05/20 Canaccord
Lionsgate price target lowered to $13 from $16 at Canaccord
02/10/20 Truist
Lionsgate price target lowered to $15 from $18 at SunTrust
01/21/20 Wells Fargo
Lionsgate downgraded to Equal Weight from Overweight at Wells Fargo
DIS Disney
$128.66 /

-1.49 (-1.14%)

09/14/20 Jefferies
ESPN deal positive for both Caesars and DraftKings, says Jefferies
09/14/20 Evercore ISI
ESPN deal could add up to material dollars for DraftKings, says Evercore
09/08/20
Fly Intel: Top five analyst upgrades
09/08/20 Deutsche Bank
Disney upgraded to Buy from Hold at Deutsche Bank
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
04/07/20 Barrington
ViacomCBS downgraded to Market Perform from Outperform at Barrington
VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

09/02/20 Barrington
ViacomCBS price target raised to $32 from $30 at Barrington
08/27/20
Fly Intel: Top five analyst upgrades
08/27/20 Wells Fargo
ViacomCBS upgraded to Equal Weight from Underweight at Wells Fargo
08/27/20 Wells Fargo
ViacomCBS upgraded to Equal Weight from Underweight at Wells Fargo
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

Periodicals
Six charged with bribing Amazon employees to boost third-party sellers, WSJ says » 16:12
09/20/20
09/20
16:12
09/20/20
16:12
AMZN

Amazon.com

$2,953.50 /

-55.17 (-1.83%)

A federal grand jury in…

A federal grand jury in Washington state has indicted six people on charges of bribing Amazon.com employees to gain advantages for third-party sellers on the e-retailer's online storefront, where its business practices have drawn increased regulatory scrutiny, The Wall Street Journal's Matt Grossman reports. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

09/18/20 RBC Capital
Amazon.com's logistics network underappreciated by investors, says RBC Capital
09/16/20 Morgan Stanley
FedEx price target raised to $250 from $110 at Morgan Stanley
09/08/20 Goldman Sachs
Goldman sticks with Sell on Apple despite 71% rally since downgrade
09/03/20 Baird
Amazon working to better handle unprecedented seasonal Q4 demand, says Baird
AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

Periodicals
TikTok owner seeking $60B valuation in U.S. deal, Bloomberg reports » 16:08
09/20/20
09/20
16:08
09/20/20
16:08
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

China's ByteDance is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Periodicals
China has reasons to like Tiktok's Trump-approved deal, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

A White House-approved…

A White House-approved plan to transform TikTok into a U.S.-based company would keep the operation of the viral short-video app, and likely the algorithm that has powered its rise, in Chinese hands, improving the deal's chances of finding favor in Beijing, which had threatened to veto a sale, The Wall Street Journal's Liza Lin reports. ByteDance's 80% stake in TikTok would allay fears in Beijing that the White House was forcing China to relinquish one of the world's hottest technology properties-or face a ban in the critical U.S. market, the author notes. Reference Link

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Periodicals
Tiktok deal facing questions over security, ownership, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

President Trump agreed in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Conference/Events
UBS consumer goods analyst to hold an analyst/industry conference call » 15:22
09/20/20
09/20
15:22
09/20/20
15:22
NKE

Nike

$114.63 /

-1.73 (-1.49%)

Consumer Analyst Sole,…

Consumer Analyst Sole, along with the former Finish Line CEO, Sam Sato, provide an update on Nike on an Analyst/Industry conference call to be held on September 23 at 12 pm.

ShowHide Related Items >><<
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

09/18/20 Needham
Nike price target raised to $132 from $113 at Needham
09/18/20 Morgan Stanley
Nike price target raised to $142 from $121 at Morgan Stanley
09/18/20 Raymond James
Nike price target raised to $121 from $115 at Raymond James
09/18/20 Barclays
Nike price target raised to $132 from $118 at Barclays
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

Conference/Events
UBS healthcare analysts to hold an analyst/industry conference call » 15:19
09/20/20
09/20
15:19
09/20/20
15:19

Healthcare Analysts Mayo,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Express participates in a conference call with Cowen » 15:10
09/20/20
09/20
15:10
09/20/20
15:10
EXPR

Express

$0.91 /

-0.0604 (-6.23%)

Cowen Retail Analyst Chen…

Cowen Retail Analyst Chen holds a conference call with CEO Baxter who provides a preview of the Company's fall assortment and a holiday update on September 24 at 11 am. Webcast Link

ShowHide Related Items >><<
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

01/27/20 B. Riley FBR
Express price target raised to $4.50 from $4 at B. Riley FBR
01/22/20 Wedbush
Wedbush 'incrementally positive' on Express following strategic update
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

Conference/Events
Cardiff Oncology to hold a KOL conference call » 15:05
09/20/20
09/20
15:05
09/20/20
15:05
CRDF

Cardiff Oncology

$8.69 /

+0.58 (+7.15%)

Management holds a Key…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

09/18/20 Maxim
Cardiff Oncology price target raised to $14 from $6 at Maxim
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

Conference/Events
Sarepta to hold a conference call » 14:56
09/20/20
09/20
14:56
09/20/20
14:56
SRPT

Sarepta

$144.60 /

+0.62 (+0.43%)

Management discuss…

Management discuss long-term functional data from the Company's gene therapy programs on a conference call to be held on September 28 at 8:30 am. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
09/10/20 Piper Sandler
Sarepta filing for SRP-9001 could still meet expectations, says Piper Sandler
09/10/20 Mizuho
Sarepta potential study delay 'largely immaterial,' says Mizuho
09/10/20 Goldman Sachs
Sarepta Phase 3 timelines 'could remain intact,' says Goldman Sachs
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

Hot Stocks
Analysis shows AstraZeneca Tagrisso demonstrated improvement in CNS DFS » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
AZN

AstraZeneca

$56.47 /

+0.53 (+0.95%)

Results from a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

Conference/Events
Merck to hold an investor briefing » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Management provides an…

Management provides an investor briefing on the company's broad oncology presentation at ESMO 2020 on a conference call to be held on September 22 at 8 am. Webcast Link

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Bristol-Myers, Exelixis announce results from Phase 3 CheckMate -9ER trial » 14:45
09/20/20
09/20
14:45
09/20/20
14:45
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Bristol Myers Squibb…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Ipsen announces results from Phase III CheckMate -9ER trial » 14:37
09/20/20
09/20
14:37
09/20/20
14:37
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Ipsen (IPSEY) announced…

Ipsen (IPSEY) announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx in combination with Bristol Myers Squibb's (BMY) Opdivo demonstrated "significant improvements" across all efficacy endpoints, including overall survival, in previously untreated advanced renal cell carcinoma. Cabometyx in combination with Opdivo reduced the risk of death by 40% versus sunitinib. In patients receiving Cabometyx in combination with Opdivo, median progression-free survival, the trial's primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively. In addition, Cabometyx in combination with Opdivo demonstrated a superior objective response rate, with twice as many patients responding compared to sunitinib, and 8% versus 5% achieved a complete response. Cabometyx in combination with Opdivo was associated with a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months. Additionally, patients treated with the combination had a much lower rate of treatment discontinuation versus sunitinib, and a significantly lower rate of treatment discontinuation due to disease progression versus sunitinib. All key efficacy results were consistent across the pre-specified International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups. Cabometyx in combination with Opdivo was well tolerated and reflected the known safety profiles of the immunotherapy and tyrosine kinase inhibitor components in previously untreated advanced RCC. The incidence of treatment-related adverse events, including any-grade and high- grade TRAEs, was slightly higher for Cabometyx in combination with Opdivo versus sunitinib, with a low rate of treatment- related discontinuations. Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life than those treated with sunitinib at most time points, according to National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 scores. Based on these efficacy and safety results from CheckMate -9ER, Ipsen and Bristol Myers Squibb have each submitted type II variation applications for Cabometyx in combination with Opdivo to the European Medicines Agency. On September 12, the EMA validated the type II variations, confirming the submissions are complete and beginning the EMA's centralized review process. In addition, Bristol Myers Squibb and Exelixis (EXEL), which has exclusive rights to commercialize and develop Cabometyx in the U.S., recently completed their respective U.S. FDA submissions for Cabometyx in combination with Opdivo and for Opdivo in combination with Cabometyx, and along with their partners, they plan to discuss the CheckMate -9ER data with regulatory authorities across the world.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Genentech presents new data from multiple Phase III studies of Tecentriq in TNBC » 14:21
09/20/20
09/20
14:21
09/20/20
14:21
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Merck announces findings from Phase 3 EORTC1325/KEYNOTE-054 trial » 14:13
09/20/20
09/20
14:13
09/20/20
14:13
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Merck, known as MSD…

Merck, known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer announced new and updated findings from the Phase 3 EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival, reducing the risk of distant metastasis or death by 40% versus placebo, with 3.5-year DMFS rates of 65.3% and 49.4%, respectively. In addition, KEYTRUDA demonstrated a sustained recurrence-free survival benefit versus placebo across stage IIIA, IIIB and IIIC melanoma, with 3.5-year RFS rates of 59.8% for KEYTRUDA versus 41.4% for placebo. The RFS and DMFS benefits were observed across key subgroups, including disease stages, BRAF mutation status and PD-L1 expression. These late-breaking data were presented as a proffered paper at the European Society for Medical Oncology Virtual Congress 2020.

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Zai Lab announced results from NORA study » 14:08
09/20/20
09/20
14:08
09/20/20
14:08
ZLAB

Zai Lab

$79.26 /

-1.29 (-1.60%)

Zai Lab has announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

08/14/20 Guggenheim
Zai Lab price target raised to $111 from $105 at Guggenheim
07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/08/20 Guggenheim
Zai Lab price target raised to $105 from $75 at Guggenheim
07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

  • 23
    Jan
On The Fly
Opening Day: Snowflake shares double in biggest software IPO ever » 08:16
09/20/20
09/20
08:16
09/20/20
08:16
CRM

Salesforce

$242.67 /

-1.855 (-0.76%)

, BRK.A

Berkshire Hathaway

$327,677.00 /

+1255.99 (+0.38%)

, BRK.B

Berkshire Hathaway

$218.05 /

+0.06 (+0.03%)

, SNOW

Snowflake

$237.60 /

+10.6 (+4.67%)

, FROG

JFrog

$65.00 /

-1.13 (-1.71%)

, SUMO

Sumo Logic

$25.21 /

-1.44 (-5.40%)

, SPLK

Splunk

$175.04 /

-2.51 (-1.41%)

, ESTC

Elastic

$103.17 /

+0.74 (+0.72%)

, U

Unity Software

$68.25 /

+ (+0.00%)

, BNL

Broadstone Net Lease

$16.67 /

+0.41 (+2.52%)

, PTVE

Pactiv Evergreen

$11.75 /

+0.68 (+6.14%)

, AMWL

Amwell

$22.96 /

-0.72 (-3.04%)

, DYN

Dyne Therapeutics

$22.80 /

-0.81 (-3.43%)

, STEP

Stepstone Group

$24.99 /

+0.09 (+0.36%)

, MTCR

Metracrine

$10.03 /

-0.32 (-3.09%)

, OM

Outset Medical

$60.22 /

-2.38 (-3.80%)

, ATHA

Athira Pharma

$17.50 /

+ (+0.00%)

, RTP

Reinvent Technology Partners

$0.00 /

+ (+0.00%)

, SBG

Sandbridge Acquisition

$0.00 /

+ (+0.00%)

, AIRB

Airbnb

$0.00 /

+ (+0.00%)

, IH

iHuman

$0.00 /

+ (+0.00%)

, ORPH

Orphazyme

$0.00 /

+ (+0.00%)

, GRAY

Graybug Vision

$0.00 /

+ (+0.00%)

, GOOG

Alphabet

$1,459.36 /

-36.47 (-2.44%)

, GOOGL

Alphabet Class A

$1,451.09 /

-37.51 (-2.52%)

, GLNG

Golar LNG

$13.93 /

+1.03 (+7.98%)

, HYGO

Hygo Energy

$0.00 /

+ (+0.00%)

, IKT

Inhibikase Therapeutics

$0.00 /

+ (+0.00%)

, TSHA

Taysha Gene Therapies

$0.00 /

+ (+0.00%)

Shares of Snowflake, a…

ShowHide Related Items >><<
SPLK Splunk
$175.04 /

-2.51 (-1.41%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

09/18/20 Baird
Salesforce benefitting from pandemic ecommerce burst, says Baird
08/26/20 Morgan Stanley
Salesforce price target raised to $275 from $195 at Morgan Stanley
08/26/20 JPMorgan
Salesforce price target raised to $250 from $200 at JPMorgan
08/26/20 Monness Crespi
Salesforce price target raised to $275 from $195 at Monness Crespi
BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

FROG JFrog
$65.00 /

-1.13 (-1.71%)

SUMO Sumo Logic
$25.21 /

-1.44 (-5.40%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

08/31/20 Argus
Splunk price target raised to $260 from $215 at Argus
08/27/20
Fly Intel: Top five analyst upgrades
08/27/20 Needham
Splunk price target raised to $250 from $192 at Needham
08/27/20 DA Davidson
Splunk price target raised to $240 from $190 at DA Davidson
ESTC Elastic
$103.17 /

+0.74 (+0.72%)

08/27/20 FBN Securities
Elastic price target raised to $125 from $95 at FBN Securities
08/27/20 Stifel
Elastic price target raised to $125 from $84 at Stifel
08/27/20 Monness Crespi
Elastic price target raised to $142 from $100 at Monness Crespi
08/27/20 DA Davidson
Elastic price target raised to $130 from $100 at DA Davidson
U Unity Software
$68.25 /

+ (+0.00%)

BNL Broadstone Net Lease
$16.67 /

+0.41 (+2.52%)

PTVE Pactiv Evergreen
$11.75 /

+0.68 (+6.14%)

AMWL Amwell
$22.96 /

-0.72 (-3.04%)

DYN Dyne Therapeutics
$22.80 /

-0.81 (-3.43%)

STEP Stepstone Group
$24.99 /

+0.09 (+0.36%)

MTCR Metracrine
$10.03 /

-0.32 (-3.09%)

OM Outset Medical
$60.22 /

-2.38 (-3.80%)

ATHA Athira Pharma
$17.50 /

+ (+0.00%)

RTP Reinvent Technology Partners
$0.00 /

+ (+0.00%)

SBG Sandbridge Acquisition
$0.00 /

+ (+0.00%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

IH iHuman
$0.00 /

+ (+0.00%)

ORPH Orphazyme
$0.00 /

+ (+0.00%)

GRAY Graybug Vision
$0.00 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

09/18/20 Morgan Stanley
AES Corp. price target raised to $23.50 from $19 at Morgan Stanley
09/14/20 KeyBanc
Alphabet initiated with an Overweight at KeyBanc
08/25/20 UBS
Alphabet price target raised to $1,970 from $1,600 at UBS
08/12/20 JPMorgan
Broadcom likely co-designed Google's next-gen AI chip, says JPMorgan
GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

09/15/20
Fly Intel: Top five analyst initiations
09/14/20 KeyBanc
Alphabet initiated with an Overweight at KeyBanc
GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

09/01/20 DNB Markets
Golar LNG upgraded to Buy from Hold at DNB Markets
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
04/08/20 B. Riley FBR
Golar LNG price target lowered to $13 from $21 at B. Riley FBR
03/09/20 DNB Markets
Golar LNG downgraded to Hold from Buy at DNB Markets
HYGO Hygo Energy
$0.00 /

+ (+0.00%)

IKT Inhibikase Therapeutics
$0.00 /

+ (+0.00%)

TSHA Taysha Gene Therapies
$0.00 /

+ (+0.00%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

  • 24
    Sep
  • 25
    Sep
  • 18
    Sep
  • 17
    Sep
  • 15
    Sep
  • 18
    Sep
  • 16
    Sep
  • 16
    Sep
  • 17
    Sep
  • 17
    Sep
  • 16
    Sep
  • 17
    Sep
  • 17
    Sep
  • 16
    Sep
U Unity Software
$68.25 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

SUMO Sumo Logic
$25.21 /

-1.44 (-5.40%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

IKT Inhibikase Therapeutics
$0.00 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

BNL Broadstone Net Lease
$16.67 /

+0.41 (+2.52%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

Periodicals
Nikola outsourced batteries on truck prototype, FT reports » 07:46
09/20/20
09/20
07:46
09/20/20
07:46
GM

General Motors

$31.50 /

-0.42 (-1.32%)

, NKLA

Nikola

$34.25 /

+0.37 (+1.09%)

Nikola (NKLA) is relying…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

09/17/20 Roth Capital
Roth raises Workhorse target to $33 after Lordstown's 'compelling' analyst day
09/17/20 Deutsche Bank
GM news 'potentially disruptive' to powertrain suppliers, says Deutsche Bank
09/14/20 JPMorgan
Core criticism of Nikola short report 'misconceived,' says JPMorgan
09/10/20 Barclays
General Motors price target raised to $39 from $34 at Barclays
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

09/16/20 JPMorgan
JPMorgan says talks with Nikola CFO 'reassuring'
09/14/20 Wedbush
Nikola remains a 'prove me' stock, says Wedbush
09/09/20 RBC Capital
Nikola price target raised to $49 from $46 at RBC Capital
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

Periodicals
Trump supports deal to allow TikTok to continue operating in U.S., Reuters says » 18:35
09/19/20
09/19
18:35
09/19/20
18:35
WMT

Walmart

$135.30 /

-1.39 (-1.02%)

, ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

President Donald Trump…

President Donald Trump said he supports a deal that will allow TikTok to continue to operate in the United States, after threatening to ban the Chinese-owned app in August, Reuters' Alexandra Alper and David Shepardson report. He told reporters at the White House he backs the deal with Oracle (ORCL) and Walmart (WMT) that would see the creation of a new company that will assume TikTok's U.S. operations, the authors note. Trump said the new TikTok company will be "totally controlled by Oracle and Walmart.... All of the control is Oracle and Walmart." Reference Link

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Hot Stocks
Immunomedics says Phase 2 'positive' in metastatic urothelial cancer » 14:25
09/19/20
09/19
14:25
09/19/20
14:25
IMMU

Immunomedics

$85.50 /

+0.19 (+0.22%)

Immunomedics announced…

Immunomedics announced "positive" results from cohort 1 of cisplatin-eligible patients in the pivotal Phase 2 TROPHY U-01 study of Trodelvy in metastatic urothelial cancer. Results confirm the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC who progressed on both platinum-based chemotherapy and checkpoint inhibitors, the company said. The median progression-free survival was 5.4 months and median overall survival was 10.5 months. "Given that only about 10 percent of patients with mUC who have cancer progression after platinum-based and CPI therapy are expected to respond to single-agent chemotherapy with approximately two to three months of median progression-free survival, today's compelling results with sacituzumab govitecan offer patients and families new hope," commented Yohann Loriot, MD, PhD, Institut de Cancerologie Gustave Roussy, Villejuif, France.

ShowHide Related Items >><<
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/17/20 Piper Sandler
Novocure price target raised to $125 from $89 at Piper Sandler
09/15/20
Fly Intel: Top analyst downgrades
09/15/20 Guggenheim
Immunomedics downgraded to Neutral from Buy at Guggenheim
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

  • 29
    Apr
  • 05
    Dec
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

Hot Stocks
Immunomedics' Trodelvy extended overall survival in breast cancer study » 14:22
09/19/20
09/19
14:22
09/19/20
14:22
IMMU

Immunomedics

$85.50 /

+0.19 (+0.22%)

Immunomedics announced…

Immunomedics announced that results from the confirmatory Phase 3 ASCENT study showed that Trodelvy "significantly extended" overall survival and improved overall response rate and clinical benefit rate, compared to treatment of choice standard single-agent chemotherapy in brain metastases-negative patients with mTNBC who had previously received at least two prior therapies for metastatic disease. Despite having received a median of four prior anticancer regimens, patients treated with Trodelvy in the ASCENT study showed a statistically significant and clinically meaningful improvement in OS with a median of 12.1 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.48, the company said. Trodelvy also demonstrated a statistically significant improvement in ORR and CBR compared to chemotherapy, Immunomedics added. Ten complete responses were observed in the Trodelvy arm compared with two in the control group. As of data cutoff on March 11, 2020, 15 patients continued to receive Trodelvy treatment while no patient remained on study in the TPC control arm. "We believe these remarkable results should facilitate the establishment of Trodelvy as a new standard of care in patients with third-line mTNBC," said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics. "We are working very collaboratively with FDA under the RTOR program to submit a supplemental Biologics License Application to have Trodelvy's label expanded to include these confirmatory new data. Additionally, we plan to submit a Marketing Authorization Application to the European Medicines Agency in the first half of 2021 in order to make this important new treatment available to mTNBC patients in Europe."

ShowHide Related Items >><<
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/17/20 Piper Sandler
Novocure price target raised to $125 from $89 at Piper Sandler
09/15/20
Fly Intel: Top analyst downgrades
09/15/20 Guggenheim
Immunomedics downgraded to Neutral from Buy at Guggenheim
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

  • 29
    Apr
  • 05
    Dec
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

Periodicals
CoreLogic battle appears headed to shareholder vote, Barron's says » 10:18
09/19/20
09/19
10:18
09/19/20
10:18
CNNE

Cannae Holdings

$36.18 /

-1.27 (-3.39%)

, CLGX

CoreLogic

$67.32 /

-0.12 (-0.18%)

One of the…

One of the more-confrontational activist battles this year is almost sure to come down to a shareholder vote in November, Carleton English writes in this week's edition of Barron's. Earlier in the week, CoreLogic (CLGX) rejected the second buyout bid by activist investor Senator Investment Group and strategic holding company Cannae Holdings (CNNE), claiming the $66-per-share offer "significantly undervalue(d)" the property data and analytics company, the author notes, adding that admittedly, the duo only increased their initial offer by $1 a share as a "gesture of good faith." They had hoped to restart talks and start a formal due-diligence process to determine if a higher bid is warranted, the report points out. With both sides at a seeming impasse, it's increasingly looking like CoreLogic shareholders will have the final say at the company's special meeting on Nov. 17 in which Senator and Cannae put up a majority slate of director nominees to facilitate a sale process. Reference Link

ShowHide Related Items >><<
CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

06/26/20 Truist
CoreLogic upgraded to Buy from Hold at SunTrust
05/14/20 Stephens
Cannae Holdings price target raised to $43 from $40 at Stephens
11/20/19 Stephens
Stephens says 'don't worry' about new CEO at Cannae Holdings
CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

07/24/20
Fly Intel: Top five analyst downgrades
07/24/20 Stephens
Stephens sees limited further upside for CoreLogic shares, cuts to Equal Weight
07/24/20 Stephens
CoreLogic downgraded to Equal Weight from Overweight at Stephens
07/24/20 Compass Point
CoreLogic downgraded to Neutral from Buy at Compass Point
CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

  • 11
    Jun
  • 04
    Dec
CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.